Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...

In a phase II trial of moderate-to-severe major depressive disorder, 6 weeks of intensive treatment with psilocybin or ...

PureTech Health has obtained approval from the US Food and Drug Administration (FDA) for KarXT to treat schizophrenia in ...

Bristol Myers Squibb wins approval for the first novel schizophrenia drug in decades; Pfizer pulls Oxbryta from the market; ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Following the acquisition of Karuna, KarXT is now under the stewardship of BMS and will be marketed as Cobenfy. Cobenfy was invented at PureTech by combining two biologically active molecules ...

After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

The medication is the first in decades to have a different mode of action than do current drugs, achieving better symptom ...

Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than antipsychotic treatments ...

We’re only a few months a way from the end of the year, but pharma companies still have a steady stream of clinical trial ...

Nine years on from securing $3.84 million for a phase I clinical trial to test the formulation, with results showing it ...